Lauren Robinson
Critical Care Medicine · Philadelphia, PANPI 1659956175
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Novo Nordisk at 53.1% of the total. Reporting peaked in 2021 at $2,360 and has fallen 95.0% since, to $118 in 2025.
Across 164 payments — averaging $27.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$618
- Sanofi-aventis U.S. LLC$565
- Xeris Pharmaceuticals, Inc.$299
- Viiv Healthcare Company$119
- GSK$118
- plus $397 from 9 others
What the payments were for
- Food & beverage$4,507100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 115 | $2,393 |
| AstraZeneca | 14 | $618 |
| Sanofi-aventis U.S. LLC | 8 | $565 |
| Xeris Pharmaceuticals, Inc. | 7 | $299 |
| Viiv Healthcare Company | 1 | $119 |
| GSK | 1 | $118 |
| Bayer | 1 | $106 |
| Amarin Pharma, Inc. | 7 | $100 |
| Lilly USA, LLC | 2 | $48 |
| Amryt Pharma Holdings Ltd | 2 | $46 |
| GRT US Holding, Inc. | 2 | $22 |
| Tandem Diabetes Care, Inc. | 1 | $22 |
| Embecta Corp. | 1 | $21 |
| Cequr Corporation | 1 | $20 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$1,038
- FARXIGA$448
- Ozempic$366
- GVOKE HYPOPEN$220
- TZIELD$143
- DOVATO$119
- SOLIQUA 100/33$119
- AREXVY$118
- TOUJEO$106
- Kerendia$106
How this compares
$4,507 in reported general payments places this provider in the 85th percentile of 354 critical care medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 45 | $52,655 |
| TrulicityDulaglutide | 34 | $50,958 |
| OzempicSemaglutide | 20 | $28,493 |
| FarxigaDapagliflozin Propanediol | 13 | $18,081 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $7,990 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $7,832 |
| Humalog Kwikpen U-100Insulin Lispro | 27 | $5,927 |
| Novolog FlexpenInsulin Aspart | 11 | $3,419 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 27 | $2,669 |
| Metformin Hcl ErMetformin Hcl | 70 | $2,530 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 23 | $2,187 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 12 | $2,157 |
| Ultra-Fine Micro Pen NeedlePen Needle, Diabetic | 21 | $1,331 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 12 | $1,316 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 13 | $1,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $48 | $50,95834 claims |
| Novo NordiskOzempic | $2,393 | $28,49320 claims |
| AstraZenecaFarxiga | $618 | $18,08113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Philadelphia
- David DibardinoPhiladelphia$63K
- Harold PalevskyPhiladelphia$55K
- Steven KawutPhiladelphia$34K
- Kerri SmithPhiladelphia$30K
- Michael BeersPhiladelphia$28K
- Daniel DorganPhiladelphia$23K
- Belinda Rivera-LebronPhiladelphia$18K
- Kevin MaPhiladelphia$15K
- Joshua DiamondPhiladelphia$13K
- Gregory TinoPhiladelphia$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.